• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SelectQuote, Inc. Reports Fourth Quarter of Fiscal Year 2025 Results

    8/21/25 7:30:00 AM ET
    $SLQT
    Specialty Insurers
    Finance
    Get the next $SLQT alert in real time by email

    Fourth Quarter of Fiscal Year 2025 – Consolidated Earnings Highlights

    • Revenue of $345.1 million
    • Net income of $12.9 million
    • Adjusted EBITDA* of $2.7 million

    Fiscal Year 2026 Guidance Ranges:

    • Revenue expected in a range of $1.650 billion to $1.750 billion
    • Adjusted EBITDA* expected in a range of $120 million to $150 million

    Fourth Quarter Fiscal Year 2025 – Segment Highlights

    Senior

    • Revenue of $82.5 million
    • Adjusted EBITDA* of $7.7 million
    • Approved Medicare Advantage policies of 85,344

    Healthcare Services

    • Revenue of $214.0 million
    • Adjusted EBITDA* of $11.9 million
    • 108,018 SelectRx members

    Life

    • Revenue of $48.0 million
    • Adjusted EBITDA* of $6.9 million

    SelectQuote, Inc. (NYSE:SLQT) reported consolidated revenue for the fourth quarter of fiscal year 2025 of $345.1 million compared to consolidated revenue for the fourth quarter of fiscal year 2024 of $307.2 million. Consolidated net income for the fourth quarter of fiscal year 2025 was $12.9 million compared to consolidated net loss for the fourth quarter of fiscal year 2024 of $31.0 million. Finally, consolidated Adjusted EBITDA* for the fourth quarter of fiscal year 2025 was $2.7 million compared to consolidated Adjusted EBITDA* for the fourth quarter of fiscal year 2024 of $14.4 million.

    Tim Danker, SelectQuote Chief Executive Officer, commented "The strength of our holistic healthcare services model was broadly exhibited in fiscal 2025, and we firmly believe the years ahead will increasingly drive substantial value for each of our stakeholders. Policyholders and patients will continue to benefit from our information advantage through tailored advice and healthcare solutions, which ultimately result in better health outcomes. Our insurance and healthcare service partners benefit from better treatment fit and adherence, which eliminates waste and serves to ease the historical trend of rising healthcare costs for Americans. Additionally, we believe our shareholders will benefit as SelectQuote's diverse breadth of revenues drive increasing cash flow, which will accelerate and compound with new growth initiatives in the future."

    Mr. Danker continued, "We are proud to have delivered financial results well in excess of our initial expectations for the 3rd consecutive year. Over that period, our Adjusted EBITDA results have outperformed our forecasts by more than 20% each year. Our leadership and workforce have accomplished these results through significant change in Medicare Advantage in each year. We credit the talent and hard work of our people and are exceedingly proud of the track record SelectQuote has built as an agile, innovative and reliable source of value for Americans seeking healthcare that best fits their needs."

    * See "Non-GAAP Financial Measures" below.

    Segment Results

    We currently have three reportable segments: 1) Senior, 2) Healthcare Services and 3) Life. The performance measures of the segments include total revenue and Adjusted EBITDA.* Costs of commissions and other services revenue, cost of goods sold-pharmacy revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect costs of revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses are allocated to each segment based on varying metrics such as headcount. Adjusted EBITDA is our segment profit measure to evaluate the operating performance of our business. We define Adjusted EBITDA as income (loss) before income tax expense (benefit) plus: (i) interest expense, net; (ii) depreciation and amortization; (iii) share-based compensation; (iv) goodwill, long-lived asset, and intangible assets impairments; (v) transaction costs; (vi) loss on disposal of property, equipment and software, net; (vii) other non-recurring expenses and income; (viii) changes in fair value of warrant liabilities. Adjusted EBITDA margin is calculated as Adjusted EBITDA divided by revenue.

    Senior

    Financial Results

    The following table provides the financial results for the Senior segment for the periods presented:

     

    Three Months Ended June 30,

     

     

     

    Year Ended June 30,

     

    (in thousands)

     

    2025

     

     

     

    2024

     

     

    % Change

     

     

    2025

     

     

     

    2024

     

     

    % Change

    Revenue

    $

    82,464

     

     

    $

    114,143

     

     

    (28

    )%

     

    $

    600,393

     

     

    $

    655,849

     

     

    (8

    )%

    Adjusted EBITDA*

     

    7,722

     

     

     

    27,872

     

     

    (72

    )%

     

     

    161,671

     

     

     

    166,744

     

     

    (3

    )%

    Adjusted EBITDA Margin*

     

    9

    %

     

     

    24

    %

     

     

     

     

    27

    %

     

     

    25

    %

     

     

    Operating Metrics

    Submitted Policies

    Submitted policies are counted when an individual completes an application with our licensed agent and provides authorization to the agent to submit the application to the insurance carrier partner. The applicant may have additional actions to take before the application will be reviewed by the insurance carrier.

    The following table shows the number of submitted policies for the periods presented:

     

    Three Months Ended June 30,

     

     

     

    Year Ended June 30,

     

     

     

    2025

     

    2024

     

    % Change

     

    2025

     

    2024

     

    % Change

    Medicare Advantage

    85,979

     

    117,091

     

    (27

    )%

     

    674,851

     

    720,027

     

    (6

    )%

    All other (1)

    21,438

     

    15,260

     

    40

    %

     

    87,413

     

    72,906

     

    20

    %

    Total

    107,417

     

    132,351

     

    (19

    )%

     

    762,264

     

    792,933

     

    (4

    )%

    (1) Represents the submitted policies for Medicare supplement, dental, vision and hearing, prescription drug plan and other.

    * See "Non-GAAP Financial Measures" below.

    Approved Policies

    Approved policies represents the number of submitted policies that were approved by our insurance carrier partners for the identified product during the indicated period. Not all approved policies will go in force.

    The following table shows the number of approved policies for the periods presented:

     

    Three Months Ended June 30,

     

     

     

    Year Ended June 30,

     

     

     

    2025

     

    2024

     

    % Change

     

    2025

     

    2024

     

    % Change

    Medicare Advantage

    85,344

     

    107,272

     

    (20

    )%

     

    592,874

     

    625,245

     

    (5

    )%

    All other (1)

    19,979

     

    13,849

     

    44

    %

     

    70,295

     

    62,419

     

    13

    %

    Total

    105,323

     

    121,121

     

    (13

    )%

     

    663,169

     

    687,664

     

    (4

    )%

    (1) Represents the approved policies for medicare supplement, dental, vision and hearing, prescription drug plan and other.

    Lifetime Value of Commissions per Approved Policy

    Lifetime value of commissions per approved policy represents commissions estimated to be collected over the estimated life of an approved policy based on multiple factors, including but not limited to, contracted commission rates, carrier mix and expected policy persistency with applied constraints. The lifetime value of commissions per approved policy is equal to the sum of the commission revenue due upon the initial sale of a policy, and when applicable, an estimate of future renewal commissions.

    The following table shows the lifetime value of commissions per approved policy for the periods presented:

     

    Three Months Ended June 30,

     

     

     

    Year Ended June 30,

     

     

    (dollars per policy):

    2025

     

    2024

     

    % Change

     

    2025

     

    2024

     

    % Change

    Medicare Advantage

    $

    837

     

    $

    847

     

    (1

    )%

     

    $

    884

     

    $

    910

     

    (3

    )%

    All other (1)

     

    125

     

     

    186

     

    (33

    )%

     

     

    134

     

     

    146

     

    (8

    )%

    (1) Represents the weighted average LTV per approved policy.

    Healthcare Services

    Financial Results

    The following table provides the financial results for the Healthcare Services segment for the periods presented:

     

    Three Months Ended June 30,

     

     

     

    Year Ended June 30,

     

     

    (in thousands)

     

    2025

     

     

     

    2024

     

     

    % Change

     

     

    2025

     

     

     

    2024

     

     

    % Change

    Revenue

    $

    214,028

     

     

    $

    145,223

     

     

    47

    %

     

    $

    742,705

     

     

    $

    478,508

     

     

    55

    %

    Adjusted EBITDA*

     

    11,853

     

     

     

    909

     

     

    1,204

    %

     

     

    25,387

     

     

     

    7,821

     

     

    225

    %

    Adjusted EBITDA Margin*

     

    6

    %

     

     

    1

    %

     

     

     

     

    3

    %

     

     

    2

    %

     

     

    Operating Metrics

    Members

    The total number of SelectRx members represents the amount of active customers to which an order has been shipped and the prescriptions per day represents the total average prescriptions shipped per business day. These two metrics are the primary drivers of revenue for Healthcare Services.

    * See "Non-GAAP Financial Measures" below.

    The following table shows the total number of SelectRx members as of the periods presented:

     

     

    June 30, 2025

     

    June 30, 2024

    Total SelectRx Members

     

    108,018

     

    82,385

    The total number of SelectRx members increased by 31% as of June 30, 2025, compared to June 30, 2024, due to our strategy to grow SelectRx membership.

    The following table shows the average prescriptions shipped per day for the periods presented:

     

     

    Three Months Ended June 30,

     

    Year Ended June 30,

     

     

    2025

     

    2024

     

    2025

     

    2024

    Prescriptions Per Day

     

    30,630

     

    22,950

     

    27,867

     

    18,935

    Combined Senior and Healthcare Services - Consumer Per Unit Economics

    Combined Senior and Healthcare Services consumer per unit economics represents total MA and MS commissions; other product commissions; other revenues, including revenues from Healthcare Services; and operating expenses associated with Senior and Healthcare Services, each shown per number of approved MA and MS policies over a given time period. Management assesses the business on a per-unit basis to help ensure that the revenue opportunity associated with a successful policy sale is attractive relative to the marketing acquisition cost. Because not all acquired leads result in a successful policy sale, all per-policy metrics are based on approved policies, which is the measure that triggers revenue recognition.

    The MA and MS commission per MA/MS policy represents the LTV for policies sold in the period. Other commission per MA/MS policy represents the LTV for other products sold in the period, including DVH prescription drug plan, and other products, which management views as additional commission revenue on our agents' core function of MA/MS policy sales. Pharmacy revenue per MA/MS policy represents revenue from SelectRx, and other revenue per MA/MS policy represents revenue from Population Health, production bonuses, marketing development funds, lead generation revenue, and adjustments from the Company's reassessment of its cohorts' transaction prices. Total operating expenses per MA/MS policy represents all of the operating expenses within Senior and Healthcare Services. The revenue to customer acquisition cost ("CAC") multiple represents total revenue as a multiple of total marketing acquisition cost, which represents the direct costs of acquiring leads. These costs are included in marketing and advertising expense within the total operating expenses per MA/MS policy.

    The following table shows combined Senior and Healthcare Services consumer per unit economics for the periods presented. Based on the seasonality of Senior and the fluctuations between quarters, we believe that the most relevant view of per unit economics is on a rolling 12-month basis. All per MA/MS policy metrics below are based on the sum of approved MA/MS policies, as both products have similar commission profiles.

     

    Twelve Months Ended June 30,

    (dollars per approved policy):

     

    2025

     

     

     

    2024

     

    MA and MS approved policies

     

    594,572

     

     

     

    627,130

     

    MA and MS commission per MA / MS policy

    $

    885

     

     

    $

    910

     

    Other commission per MA/MS policy

     

    12

     

     

     

    12

     

    Pharmacy revenue per MA/MS policy

     

    1,219

     

     

     

    741

     

    Other revenue per MA/MS policy

     

    86

     

     

     

    146

     

    Total revenue per MA / MS policy

     

    2,202

     

     

     

    1,809

     

    Total operating expenses per MA / MS policy

     

    (1,937

    )

     

     

    (1,530

    )

    Adjusted EBITDA per MA/MS policy *

    $

    265

     

     

    $

    279

     

    Adjusted EBITDA Margin per MA/MS policy *

     

    12

    %

     

     

    15

    %

    Revenue / CAC multiple

    6.1X

     

    4.5X

    Total revenue per MA/MS policy increased 22% for the twelve months ended June 30, 2025, compared to the twelve months ended June 30, 2024, primarily due to the increase in pharmacy revenue. Total operating expenses per MA/MS policy increased 27% for the twelve months ended June 30, 2025, compared to the twelve months ended June 30, 2024, driven by an increase in cost of goods sold-pharmacy revenue for Healthcare Services due to the growth of the business.

    Life

    Financial Results

    The following table provides the financial results for the Life segment for the periods presented:

     

    Three Months Ended June 30,

     

     

     

    Year Ended June 30,

     

     

    (in thousands)

     

    2025

     

     

     

    2024

     

     

    % Change

     

     

    2025

     

     

     

    2024

     

     

    % Change

    Revenue

    $

    47,984

     

     

    $

    42,074

     

     

    14

    %

     

    $

    172,978

     

     

    $

    157,930

     

     

    10

    %

    Adjusted EBITDA*

     

    6,922

     

     

     

    7,217

     

     

    (4

    )%

     

     

    26,669

     

     

     

    20,164

     

     

    32

    %

    Adjusted EBITDA Margin*

     

    14

    %

     

     

    17

    %

     

     

     

     

    15

    %

     

     

    13

    %

     

     

    Operating Metrics

    Life premium represents the total premium value for all policies that were approved by the relevant insurance carrier partner and for which the policy document was sent to the policyholder and payment information was received by the relevant insurance carrier partner during the indicated period. Because our commissions are earned based on a percentage of total premium, total premium volume for a given period is the key driver of revenue for our Life segment.

    The following table shows term and final expense premiums for the periods presented:

     

    Three Months Ended June 30,

     

     

     

    Year Ended June 30,

     

     

    (in thousands)

    2025

     

    2024

     

    % Change

     

    2025

     

    2024

     

    % Change

    Term Premiums

    $

    19,989

     

    $

    18,074

     

    11

    %

     

    $

    71,448

     

    $

    70,450

     

    1

    %

    Final Expense Premiums

     

    30,807

     

     

    23,789

     

    30

    %

     

     

    105,099

     

     

    86,600

     

    21

    %

    Total

    $

    50,796

     

    $

    41,863

     

    21

    %

     

    $

    176,547

     

    $

    157,050

     

    12

    %

    * See "Non-GAAP Financial Measures" below.

    Earnings Conference Call

    SelectQuote, Inc. will host a conference call with the investment community on August 21, 2025, beginning at 8:30 a.m. ET. To register for this conference call, please use this link: https://registrations.events/direct/Q4I547808. After registering, a confirmation will be sent via email, including dial-in details and unique conference call codes for entry. Registration is open through the live call, but to ensure you are connected for the full call we suggest registering at least 10 minutes before the start of the call. The event will also be webcasted live via our investor relations website https://ir.selectquote.com/investor-home/default.aspx.

    Non-GAAP Financial Measures

    This release includes certain non-GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our GAAP financial results, we have presented in this release Adjusted EBITDA, which is a non-GAAP financial measure. This non-GAAP financial measure is not based on any standardized methodology prescribed by GAAP and is not necessarily comparable to any similarly titled measure presented by other companies. We define Adjusted EBITDA as net income (loss) before income tax expense (benefit), plus interest expense, depreciation and amortization, changes in fair value of warrant liabilities, and certain add-backs for non-cash or non-recurring expenses, including restructuring and share-based compensation expenses. The most directly comparable GAAP measure is net income (loss) before income tax expense (benefit). We monitor and have presented in this release Adjusted EBITDA because it is a key measure used by our management and Board of Directors to understand and evaluate our operating performance, establish budgets, and develop operational goals for managing our business. In particular, we believe that excluding the impact of these expenses in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core operating performance.

    Reconciliations of net income (loss) before income tax expense (benefit) to Adjusted EBITDA are presented below beginning on page 12. The Company is unable to provide a quantitative reconciliation of forward-looking Adjusted EBITDA to its most directly comparable GAAP measure without unreasonable effort because it is not possible to predict certain information included in the calculation of such GAAP measure, including the fair value of outstanding warrants to purchase shares of the Company's common stock. The unavailable information could have a significant impact on the Company's GAAP financial results.

    Forward Looking Statements

    This release contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as "may," "should," "could," "predict," "potential," "believe," "will likely result," "expect," "continue," "will," "anticipate," "seek," "estimate," "intend," "plan," "projection," "would" and "outlook," or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts and are based on current expectations, estimates and projections about our industry, management's beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements.

    There are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: our reliance on a limited number of insurance carrier partners and any potential termination of those relationships or failure to develop new relationships; existing and future laws and regulations affecting the health insurance market; changes in health insurance products offered by our insurance carrier partners and the health insurance market generally; insurance carriers offering products and services directly to consumers; changes to commissions paid by insurance carriers and underwriting practices; competition with brokers, exclusively online brokers and carriers who opt to sell policies directly to consumers; competition from government-run health insurance exchanges; developments in the U.S. health insurance system; our dependence on revenue from carriers in our senior segment and downturns in the senior health as well as life, automotive and home insurance industries; our ability to develop new offerings and penetrate new vertical markets; risks from third-party products; failure to enroll individuals during the Medicare annual enrollment period; our ability to attract, integrate and retain qualified personnel; our dependence on lead providers and ability to compete for leads; failure to obtain and/or convert sales leads to actual sales of insurance policies; access to data from consumers and insurance carriers; accuracy of information provided from and to consumers during the insurance shopping process; cost-effective advertisement through internet search engines; ability to contact consumers and market products by telephone; global economic conditions, including inflation and tariffs; disruption to operations as a result of future acquisitions; significant estimates and assumptions in the preparation of our financial statements; impairment of goodwill; existing or potential litigation and other legal proceedings or inquiries, including the Department of Justice action alleging violations of the federal False Claims Act; our existing and future indebtedness; our ability to maintain compliance with our debt covenants; access to additional capital; failure to protect our intellectual property and our brand; fluctuations in our financial results caused by seasonality; accuracy and timeliness of commissions reports from insurance carriers; timing of insurance carriers' approval and payment practices; factors that impact our estimate of the constrained lifetime value of commissions per policyholder; changes in accounting rules, tax legislation and other legislation; disruptions or failures of our technological infrastructure and platform; failure to maintain relationships with third-party service providers; cybersecurity breaches or other attacks involving our systems or those of our insurance carrier partners or third-party service providers; our ability to protect consumer information and other data; failure to market and sell Medicare plans effectively or in compliance with laws; and other factors related to our pharmacy business, including manufacturing or supply chain disruptions, access to and demand for prescription drugs, contractual reimbursement rates, and regulatory changes or other industry developments that may affect our pharmacy operations. For a further discussion of these and other risk factors that could impact our future results and performance, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2025 (the "Annual Report") and subsequent periodic reports filed by us with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise..

    About SelectQuote:

    Founded in 1985, SelectQuote (NYSE:SLQT) pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies, allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote's success: a strong force of highly-trained and skilled agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads. Today, the Company operates an ecosystem offering high touchpoints for consumers across insurance, pharmacy, and virtual care.

    With an ecosystem offering engagement points for consumers across insurance, Medicare, pharmacy, and value-based care, the company now has three core business lines: SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a Patient-Centered Pharmacy Home™ (PCPH) accredited pharmacy, SelectPatient Management, a provider of chronic care management services, and Healthcare Select which proactively connects consumers with a wide breadth of healthcare services supporting their needs.

    Source: SelectQuote, Inc.

    SELECTQUOTE, INC. AND SUBSIDIARIES

    CONSOLIDATED BALANCE SHEETS

    (Unaudited)

    (In thousands)

     

     

    June 30, 2025

     

    June 30, 2024

    ASSETS

     

     

     

    CURRENT ASSETS:

     

     

     

    Cash, cash equivalents, and restricted cash

    $

    35,733

     

     

    $

    42,690

     

    Accounts receivable, net of allowances of $11.8 million and $8.2 million, respectively

     

    151,388

     

     

     

    150,035

     

    Commissions receivable-current

     

    132,077

     

     

     

    119,871

     

    Other current assets

     

    21,844

     

     

     

    20,327

     

    Total current assets

     

    341,042

     

     

     

    332,923

     

    COMMISSIONS RECEIVABLE—Net

     

    818,751

     

     

     

    761,446

     

    PROPERTY AND EQUIPMENT—Net

     

    14,577

     

     

     

    18,973

     

    SOFTWARE—Net

     

    15,060

     

     

     

    13,978

     

    OPERATING LEASE RIGHT-OF-USE ASSETS

     

    24,635

     

     

     

    23,437

     

    INTANGIBLE ASSETS—Net

     

    1,973

     

     

     

    10,194

     

    GOODWILL

     

    29,438

     

     

     

    29,438

     

    OTHER ASSETS

     

    3,880

     

     

     

    3,519

     

    TOTAL ASSETS

    $

    1,249,356

     

     

    $

    1,193,908

     

     

     

     

     

    LIABILITIES, PREFERRED STOCK, AND SHAREHOLDERS' EQUITY

     

     

     

    CURRENT LIABILITIES:

     

     

     

    Accounts payable

    $

    59,205

     

     

    $

    36,587

     

    Accrued expenses

     

    13,856

     

     

     

    16,904

     

    Accrued compensation and benefits

     

    58,788

     

     

     

    57,594

     

    Operating lease liabilities—current

     

    4,820

     

     

     

    4,709

     

    Current portion of long-term debt

     

    68,523

     

     

     

    45,854

     

    Contract liabilities

     

    698

     

     

     

    8,066

     

    Other current liabilities

     

    7,020

     

     

     

    4,873

     

    Total current liabilities

     

    212,910

     

     

     

    174,587

     

    LONG-TERM DEBT, NET—less current portion

     

    316,589

     

     

     

    637,480

     

    DEFERRED INCOME TAXES

     

    37,872

     

     

     

    37,478

     

    OPERATING LEASE LIABILITIES

     

    25,982

     

     

     

    25,685

     

    OTHER LIABILITIES

     

    80,485

     

     

     

    1,877

     

    Total liabilities

     

    673,838

     

     

     

    877,107

     

     

     

     

     

    COMMITMENTS AND CONTINGENCIES

     

     

     

    PREFERRED STOCK:

     

     

     

    Senior Non-Convertible Preferred Stock, $0.01 par value, 350,000 shares and no shares issued and outstanding as of June 30, 2025 and June 30, 2024, respectively, current liquidation preference of $367.1 million and $0.0 million as of June 30, 2025 and June 30, 2024, respectively

     

    224,374

     

     

     

    —

     

    SHAREHOLDERS' EQUITY:

     

     

     

    Common stock, $0.01 par value

     

    1,728

     

     

     

    1,694

     

    Additional paid-in capital

     

    571,605

     

     

     

    580,764

     

    Accumulated deficit

     

    (222,189

    )

     

     

    (269,769

    )

    Accumulated other comprehensive income

     

    —

     

     

     

    4,112

     

    Total shareholders' equity

     

    351,144

     

     

     

    316,801

     

    TOTAL LIABILITIES, PREFERRED STOCK, AND SHAREHOLDERS' EQUITY

    $

    1,249,356

     

     

    $

    1,193,908

     

    SELECTQUOTE, INC. AND SUBSIDIARIES

    CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

    (Unaudited)

    (In thousands)

     

     

    Three Months Ended June 30,

     

    Year Ended June 30,

     

     

    2025

     

     

     

    2024

     

     

     

    2025

     

     

     

    2024

     

    REVENUE:

     

     

     

     

     

     

     

    Commissions and other services

    $

    134,503

     

     

    $

    165,656

     

     

    $

    797,841

     

     

    $

    856,923

     

    Pharmacy

     

    210,599

     

     

     

    141,552

     

     

     

    728,753

     

     

     

    464,853

     

    Total revenue

     

    345,102

     

     

     

    307,208

     

     

     

    1,526,594

     

     

     

    1,321,776

     

     

     

     

     

     

     

     

     

    OPERATING COSTS AND EXPENSES:

     

     

     

     

     

     

     

    Cost of commissions and other services revenue

     

    58,844

     

     

     

    64,548

     

     

     

    305,127

     

     

     

    318,798

     

    Cost of goods sold—pharmacy revenue

     

    182,312

     

     

     

    120,644

     

     

     

    630,340

     

     

     

    405,004

     

    Marketing and advertising

     

    65,283

     

     

     

    70,181

     

     

     

    319,505

     

     

     

    358,858

     

    Selling, general, and administrative

     

    9,594

     

     

     

    43,993

     

     

     

    164,442

     

     

     

    141,042

     

    Technical development

     

    41,591

     

     

     

    9,233

     

     

     

    38,681

     

     

     

    33,524

     

    Total operating costs and expenses

     

    357,624

     

     

     

    308,599

     

     

     

    1,458,095

     

     

     

    1,257,226

     

     

     

     

     

     

     

     

     

    INCOME (LOSS) FROM OPERATIONS

     

    (12,522

    )

     

     

    (1,391

    )

     

     

    68,499

     

     

     

    64,550

     

     

     

     

     

     

     

     

     

    INTEREST EXPENSE, NET

     

    (12,226

    )

     

     

    (23,409

    )

     

     

    (79,385

    )

     

     

    (93,551

    )

    CHANGE IN FAIR VALUE OF WARRANTS

     

    34,181

     

     

     

    —

     

     

     

    59,525

     

     

     

    —

     

    OTHER EXPENSE, NET

     

    (58

    )

     

     

    (15

    )

     

     

    (128

    )

     

     

    (65

    )

    INCOME (LOSS) BEFORE INCOME TAX EXPENSE (BENEFIT)

     

    9,375

     

     

     

    (24,815

    )

     

     

    48,511

     

     

     

    (29,066

    )

    INCOME TAX EXPENSE (BENEFIT)

     

    (3,493

    )

     

     

    6,202

     

     

     

    931

     

     

     

    5,059

     

     

     

     

     

     

     

     

     

    NET INCOME (LOSS)

    $

    12,868

     

     

    $

    (31,017

    )

     

    $

    47,580

     

     

    $

    (34,125

    )

    Senior Non-Convertible Preferred Stock accumulated dividends and accretion

    $

    (16,762

    )

     

    $

    —

     

     

    $

    (22,548

    )

     

    $

    —

     

    NET INCOME (LOSS) ATTRIBUTABLE TO COMMON SHAREHOLDERS

    $

    (3,894

    )

     

    $

    (31,017

    )

     

    $

    25,032

     

     

    $

    (34,125

    )

     

     

     

     

     

     

     

     

    NET INCOME (LOSS) ATTRIBUTABLE TO COMMON SHAREHOLDERS PER SHARE:

     

     

     

     

     

     

     

    Basic

    $

    (0.02

    )

     

    $

    (0.18

    )

     

    $

    0.14

     

     

    $

    (0.20

    )

    Diluted

    $

    (0.02

    )

     

    $

    (0.18

    )

     

    $

    0.01

     

     

    $

    (0.20

    )

     

     

     

     

     

     

     

     

    WEIGHTED-AVERAGE COMMON STOCK OUTSTANDING USED IN PER SHARE AMOUNTS:

     

     

     

     

     

     

     

    Basic

     

    184,201

     

     

     

    169,204

     

     

     

    176,148

     

     

     

    168,519

     

    Diluted

     

    184,201

     

     

     

    169,204

     

     

     

    181,895

     

     

     

    168,519

     

     

     

     

     

     

     

     

     

    OTHER COMPREHENSIVE LOSS NET OF TAX:

     

     

     

     

     

     

     

    Change in cash flow hedge

     

    —

     

     

     

    (2,364

    )

     

     

    (4,112

    )

     

     

    (9,567

    )

    OTHER COMPREHENSIVE LOSS

     

    —

     

     

     

    (2,364

    )

     

     

    (4,112

    )

     

     

    (9,567

    )

    COMPREHENSIVE INCOME (LOSS)

    $

    12,868

     

     

    $

    (33,381

    )

     

    $

    43,468

     

     

    $

    (43,692

    )

    SELECTQUOTE, INC. AND SUBSIDIARIES

    CONSOLIDATED STATEMENTS OF CASH FLOWS

    (Unaudited)

    (In thousands)

     

     

    Three Months Ended June 30,

     

    Year Ended June 30,

     

     

    2025

     

     

     

    2024

     

     

     

    2025

     

     

     

    2024

     

    CASH FLOWS FROM OPERATING ACTIVITIES:

     

     

     

     

     

     

     

    Net income (loss)

    $

    12,868

     

     

    $

    (31,017

    )

     

    $

    47,580

     

     

    $

    (34,125

    )

    Adjustments to reconcile net income (loss) to net cash, cash equivalents, and restricted cash used in operating activities:

     

     

     

     

     

     

     

    Depreciation and amortization

     

    4,876

     

     

     

    6,407

     

     

     

    20,460

     

     

     

    24,998

     

    Loss on disposal of property, equipment, and software

     

    80

     

     

     

    523

     

     

     

    240

     

     

     

    536

     

    Impairment of long-lived assets

     

    4,209

     

     

     

    —

     

     

     

    4,209

     

     

     

    —

     

    Share-based compensation expense

     

    4,852

     

     

     

    3,304

     

     

     

    18,357

     

     

     

    13,816

     

    Deferred income taxes

     

    (2,576

    )

     

     

    3,314

     

     

     

    1,849

     

     

     

    1,163

     

    Amortization of debt issuance costs and debt discount

     

    1,367

     

     

     

    1,279

     

     

     

    5,247

     

     

     

    6,142

     

    Write-off of debt issuance costs

     

    —

     

     

     

    —

     

     

     

    93

     

     

     

    293

     

    Accrued interest payable in kind

     

    713

     

     

     

    5,254

     

     

     

    14,013

     

     

     

    19,577

     

    Change in fair value of warrants

     

    (34,181

    )

     

     

    —

     

     

     

    (59,525

    )

     

     

    —

     

    Non-cash lease expense

     

    1,072

     

     

     

    404

     

     

     

    3,922

     

     

     

    2,349

     

    Bad debt expense

     

    —

     

     

     

    —

     

     

     

    4,203

     

     

     

    —

     

    Changes in operating assets and liabilities:

     

     

     

     

     

     

     

    Accounts receivable, net

     

    33,491

     

     

     

    103,722

     

     

     

    (5,555

    )

     

     

    5,203

     

    Commissions receivable

     

    (35,745

    )

     

     

    (48,194

    )

     

     

    (69,510

    )

     

     

    (40,819

    )

    Other assets

     

    (5,938

    )

     

     

    653

     

     

     

    (6,282

    )

     

     

    (1,967

    )

    Accounts payable and accrued expenses

     

    (21,936

    )

     

     

    (28,726

    )

     

     

    19,226

     

     

     

    7,347

     

    Operating lease liabilities

     

    (1,137

    )

     

     

    (1,095

    )

     

     

    (4,711

    )

     

     

    (4,897

    )

    Other liabilities

     

    503

     

     

     

    4,167

     

     

     

    (5,482

    )

     

     

    15,620

     

    Net cash provided by (used in) operating activities

     

    (37,482

    )

     

     

    19,995

     

     

     

    (11,666

    )

     

     

    15,236

     

    CASH FLOWS FROM INVESTING ACTIVITIES:

     

     

     

     

     

     

     

    Purchases of property and equipment

     

    (501

    )

     

     

    (268

    )

     

     

    (2,191

    )

     

     

    (3,382

    )

    Proceeds from sales of property and equipment

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    253

     

    Purchases of software and capitalized software development costs

     

    (2,610

    )

     

     

    (2,219

    )

     

     

    (9,123

    )

     

     

    (8,284

    )

    Acquisition of business

     

    —

     

     

     

    (3,433

    )

     

     

    —

     

     

     

    (3,433

    )

    Net cash used in investing activities

     

    (3,111

    )

     

     

    (5,920

    )

     

     

    (11,314

    )

     

     

    (14,846

    )

    CASH FLOWS FROM FINANCING ACTIVITIES:

     

     

     

     

     

     

     

    Proceeds from revolving line of credit

     

    —

     

     

     

    —

     

     

     

    166,900

     

     

     

    —

     

    Payments on revolving line of credit

     

    —

     

     

     

    —

     

     

     

    (166,900

    )

     

     

    —

     

    Payments on Term Loans

     

    (3,573

    )

     

     

    (8,471

    )

     

     

    (388,216

    )

     

     

    (38,883

    )

    Proceeds from ABS Notes

     

    —

     

     

     

    —

     

     

     

    99,095

     

     

     

    —

     

    Payments on ABS Notes

     

    (4,855

    )

     

     

    —

     

     

     

    (16,577

    )

     

     

    —

     

    Payments on other debt

     

    (108

    )

     

     

    (37

    )

     

     

    (312

    )

     

     

    (149

    )

    Proceeds from common stock options exercised and employee stock purchase plan

     

    (14

    )

     

     

    74

     

     

     

    98

     

     

     

    81

     

    Proceeds from issuance of Senior Non-Convertible Preferred Stock

     

    —

     

     

     

    —

     

     

     

    337,855

     

     

     

    —

     

    Senior Non-Convertible Preferred Stock issuance costs

     

    —

     

     

     

    —

     

     

     

    (7,076

    )

     

     

    —

     

    Payments of tax withholdings related to net share settlement of equity awards

     

    (13

    )

     

     

    (1

    )

     

     

    (5,032

    )

     

     

    (374

    )

    Payments of debt issuance costs

     

    —

     

     

     

    (758

    )

     

     

    (2,479

    )

     

     

    (1,531

    )

    Net cash provided by (used in) financing activities

     

    (8,563

    )

     

     

    (9,193

    )

     

     

    17,356

     

     

     

    (40,856

    )

    NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

     

    (49,156

    )

     

     

    4,882

     

     

     

    (5,624

    )

     

     

    (40,466

    )

    CASH, CASH EQUIVALENTS AND RESTRICTED CASH —Beginning of period

     

    86,222

     

     

     

    37,808

     

     

     

    42,690

     

     

     

    83,156

     

    CASH, CASH EQUIVALENTS AND RESTRICTED CASH —End of period

    $

    37,066

     

     

    $

    42,690

     

     

    $

    37,066

     

     

    $

    42,690

     

    SELECTQUOTE, INC. AND SUBSIDIARIES

    Adjusted EBITDA to Income (Loss) before income tax expense (benefit) Reconciliation

    (Unaudited)

     

     

    Three Months Ended June 30, 2025

    (in thousands)

    Senior

     

    Healthcare Services

     

    Life

     

    Total

    Total revenue from reportable segments

    $

    82,464

     

     

    $

    214,028

     

     

    $

    47,984

     

     

    $

    344,476

     

    Less:

     

     

     

     

     

     

     

    Cost of commissions and other services revenue

     

    (32,391

    )

     

     

    (5,536

    )

     

     

    (18,020

    )

     

     

    Cost of goods sold - pharmacy revenue

     

    —

     

     

     

    (180,988

    )

     

     

    —

     

     

     

    Marketing expense

     

    (41,752

    )

     

     

    (1,950

    )

     

     

    (22,813

    )

     

     

    Technical development

     

    —

     

     

     

    (495

    )

     

     

    —

     

     

     

    Selling, general, and administrative

     

    (599

    )

     

     

    (13,206

    )

     

     

    (229

    )

     

     

    Adjusted Segment EBITDA

     

    7,722

     

     

     

    11,853

     

     

     

    6,922

     

     

     

    26,497

     

    Reconciliation of total segment Adjusted EBITDA

     

     

     

     

     

     

     

    All other Adjusted EBITDA

     

     

     

     

     

     

     

    950

     

    Corporate

     

     

     

     

     

     

     

    (24,753

    )

    Share-based compensation expense

     

     

     

     

     

     

     

    (4,852

    )

    Transaction costs

     

     

     

     

     

     

     

    (1,257

    )

    Depreciation and amortization

     

     

     

     

     

     

     

    (4,876

    )

    Loss on disposal of property, equipment, and software, net

     

     

     

     

     

     

     

    (80

    )

    Impairment of long-lived assets

     

     

     

     

     

     

     

    (4,209

    )

    Change in fair value of warrants

     

     

     

     

     

     

     

    34,181

     

    Interest expense, net

     

     

     

     

     

     

     

    (12,226

    )

    Income before income tax expense (benefit)

     

     

     

     

     

     

    $

    9,375

     

     

    Three Months Ended June 30, 2024

    (in thousands)

    Senior

     

    Healthcare Services

     

    Life

     

    Total

    Total revenue from reportable segments

    $

    114,143

     

     

    $

    145,223

     

     

    $

    42,074

     

     

    $

    301,440

     

    Less:

     

     

     

     

     

     

     

    Cost of commissions and other services revenue

     

    (37,534

    )

     

     

    (5,025

    )

     

     

    (15,287

    )

     

     

    Cost of goods sold - pharmacy revenue

     

    —

     

     

     

    (119,520

    )

     

     

    —

     

     

     

    Marketing expense

     

    (48,138

    )

     

     

    (1,700

    )

     

     

    (19,279

    )

     

     

    Technical development

     

    —

     

     

     

    (835

    )

     

     

    —

     

     

     

    Selling, general, and administrative

     

    (599

    )

     

     

    (17,234

    )

     

     

    (291

    )

     

     

    Adjusted Segment EBITDA

     

    27,872

     

     

     

    909

     

     

     

    7,217

     

     

     

    35,998

     

    Reconciliation of total segment Adjusted EBITDA

     

     

     

     

     

     

     

    All other Adjusted EBITDA

     

     

     

     

     

     

     

    2,474

     

    Corporate

     

     

     

     

     

     

     

    (24,115

    )

    Share-based compensation expense

     

     

     

     

     

     

     

    (3,304

    )

    Transaction costs

     

     

     

     

     

     

     

    (5,529

    )

    Depreciation and amortization

     

     

     

     

     

     

     

    (6,407

    )

    Loss on disposal of property, equipment, and software, net

     

     

     

     

     

     

     

    (523

    )

    Interest expense, net

     

     

     

     

     

     

     

    (23,409

    )

    Loss before income tax expense (benefit)

     

     

     

     

     

     

    $

    (24,815

    )

    SELECTQUOTE, INC. AND SUBSIDIARIES

    Adjusted EBITDA to Income (Loss) before income tax expense (benefit) Reconciliation

    (Unaudited)

     

     

    Year Ended June 30, 2025

    (in thousands)

    Senior

     

    Healthcare Services

     

    Life

     

    Total

    Total revenue from reportable segments

    $

    600,393

     

     

    $

    742,705

     

     

    $

    172,978

     

     

    $

    1,516,076

     

    Less:

     

     

     

     

     

     

     

    Cost of commissions and other services revenue

     

    (201,933

    )

     

     

    (25,163

    )

     

     

    (65,047

    )

     

     

    Cost of goods sold - pharmacy revenue

     

    —

     

     

     

    (625,389

    )

     

     

    —

     

     

     

    Marketing expense

     

    (234,335

    )

     

     

    (8,038

    )

     

     

    (80,269

    )

     

     

    Technical development

     

    —

     

     

     

    (2,187

    )

     

     

    —

     

     

     

    Selling, general, and administrative

     

    (2,454

    )

     

     

    (56,541

    )

     

     

    (993

    )

     

     

    Adjusted Segment EBITDA

     

    161,671

     

     

     

    25,387

     

     

     

    26,669

     

     

     

    213,727

     

    Reconciliation of total segment Adjusted EBITDA

     

     

     

     

     

     

     

    All other Adjusted EBITDA

     

     

     

     

     

     

     

    10,597

     

    Corporate

     

     

     

     

     

     

     

    (98,070

    )

    Share-based compensation expense

     

     

     

     

     

     

     

    (18,357

    )

    Transaction costs

     

     

     

     

     

     

     

    (14,617

    )

    Depreciation and amortization

     

     

     

     

     

     

     

    (20,460

    )

    Loss on disposal of property, equipment, and software, net

     

     

     

     

     

     

     

    (240

    )

    Impairment of long-lived assets

     

     

     

     

     

     

     

    (4,209

    )

    Change in fair value of warrants

     

     

     

     

     

     

     

    59,525

     

    Interest expense, net

     

     

     

     

     

     

     

    (79,385

    )

    Income before income tax expense (benefit)

     

     

     

     

     

     

    $

    48,511

     

     

    Year Ended June 30, 2024

    (in thousands)

    Senior

     

    Healthcare Services

     

    Life

     

    Total

    Total revenue from reportable segments

    $

    655,849

     

     

    $

    478,508

     

     

    $

    157,930

     

     

    $

    1,292,287

     

    Less:

     

     

     

     

     

     

     

    Cost of commissions and other services revenue

     

    (216,348

    )

     

     

    (17,438

    )

     

     

    (60,017

    )

     

     

    Cost of goods sold - pharmacy revenue

     

    —

     

     

     

    (400,821

    )

     

     

    —

     

     

     

    Marketing expense

     

    (269,867

    )

     

     

    (6,260

    )

     

     

    (76,513

    )

     

     

    Technical development

     

    —

     

     

     

    (915

    )

     

     

    —

     

     

     

    Selling, general, and administrative

     

    (2,890

    )

     

     

    (45,253

    )

     

     

    (1,236

    )

     

     

    Adjusted Segment EBITDA

     

    166,744

     

     

     

    7,821

     

     

     

    20,164

     

     

     

    194,729

     

    Reconciliation of total segment Adjusted EBITDA  

    All other Adjusted EBITDA

     

     

     

     

     

     

     

    14,127

     

    Corporate

     

     

     

     

     

     

     

    (91,863

    )

    Share-based compensation expense

     

     

     

     

     

     

     

    (13,816

    )

    Transaction costs

     

     

     

     

     

     

     

    (13,158

    )

    Depreciation and amortization

     

     

     

     

     

     

     

    (24,998

    )

    Loss on disposal of property, equipment, and software, net

     

     

     

     

     

     

     

    (536

    )

    Interest expense, net

     

     

     

     

     

     

     

    (93,551

    )

    Loss before income tax expense (benefit)

     

     

     

     

     

     

    $

    (29,066

    )

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250821115007/en/

    Investor Relations:

    Sloan Bohlen

    877-678-4083

    [email protected]



    Media:

    Matt Gunter

    913-286-4931

    [email protected]

    Get the next $SLQT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SLQT

    DatePrice TargetRatingAnalyst
    5/21/2025$2.75Hold
    Jefferies
    9/30/2024$4.50Buy
    Craig Hallum
    2/29/2024$5.00Outperform
    Noble Capital Markets
    4/1/2022$4.00Neutral
    Credit Suisse
    2/8/2022$9.00 → $5.00Equal Weight
    Barclays
    2/8/2022$13.00 → $3.00Sector Perform
    RBC Capital
    2/8/2022$20.00 → $4.00Overweight → Neutral
    Piper Sandler
    2/8/2022$14.00 → $4.00Outperform → Neutral
    Credit Suisse
    More analyst ratings

    $SLQT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SelectQuote, Inc. Reports Fourth Quarter of Fiscal Year 2025 Results

    Fourth Quarter of Fiscal Year 2025 – Consolidated Earnings Highlights Revenue of $345.1 million Net income of $12.9 million Adjusted EBITDA* of $2.7 million Fiscal Year 2026 Guidance Ranges: Revenue expected in a range of $1.650 billion to $1.750 billion Adjusted EBITDA* expected in a range of $120 million to $150 million Fourth Quarter Fiscal Year 2025 – Segment Highlights Senior Revenue of $82.5 million Adjusted EBITDA* of $7.7 million Approved Medicare Advantage policies of 85,344 Healthcare Services Revenue of $214.0 million Adjusted EBITDA* of $11.9 million 108,018 SelectRx members Life Revenue of $48.0 million Adjusted EBITDA* of $6

    8/21/25 7:30:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    SelectQuote to Release Fiscal Fourth Quarter and Full Year 2025 Earnings on August 21

    SelectQuote, Inc. (NYSE:SLQT), a leading distributor of Medicare insurance policies and owner of a rapidly growing Healthcare Services platform, today announced it will release its fourth quarter and full year 2025 financial results before market open on Thursday, August 21, 2025. Chief Executive Officer, Tim Danker, and Chief Financial Officer, Ryan Clement, will host a conference call on the day of the release (August 21, 2025) at 8:30 am ET to discuss the results. To register for this conference call, please use this link: https://registrations.events/direct/Q4I547808. After registering, a confirmation will be sent via email, including dial in details and unique conference call codes

    8/7/25 7:30:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    SelectQuote Unveils New Program Designed to Elevate Health Plan Performance by Improving Medication Adherence for Polychronic Medicare Beneficiaries

    SelectQuote, Inc. (NYSE:SLQT) (the "Company"), a leading distributor of Medicare insurance policies and owner of a rapidly-growing healthcare services platform, today announced the expanded launch of their innovative concierge-like service designed to specifically improve medication adherence for Medicare beneficiaries managing multiple chronic conditions and complex medication regimens. SelectQuote's SelectRx pharmacy recently trialed a new approach with a regional health plan that demonstrated over 90% adherence, strengthening HEDIS Star ratings across the triple-weighted cholesterol, diabetes and hypertension measures. The Company plans to expand to additional payers this calendar year a

    7/17/25 7:00:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on SelectQuote with a new price target

    Jefferies initiated coverage of SelectQuote with a rating of Hold and set a new price target of $2.75

    5/21/25 8:59:27 AM ET
    $SLQT
    Specialty Insurers
    Finance

    Craig Hallum initiated coverage on SelectQuote with a new price target

    Craig Hallum initiated coverage of SelectQuote with a rating of Buy and set a new price target of $4.50

    9/30/24 8:47:10 AM ET
    $SLQT
    Specialty Insurers
    Finance

    Noble Capital Markets initiated coverage on SelectQuote with a new price target

    Noble Capital Markets initiated coverage of SelectQuote with a rating of Outperform and set a new price target of $5.00

    2/29/24 8:29:44 AM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Clement Ryan Moore covered exercise/tax liability with 62,002 shares and converted options into 211,240 shares, increasing direct ownership by 96% to 304,705 units (SEC Form 4)

    4 - SelectQuote, Inc. (0001794783) (Issuer)

    8/5/25 9:24:57 PM ET
    $SLQT
    Specialty Insurers
    Finance

    President, SelectQuote Senior Matthews Joshua Brandon converted options into 144,321 shares, increasing direct ownership by 30% to 625,944 units (SEC Form 4)

    4 - SelectQuote, Inc. (0001794783) (Issuer)

    8/5/25 9:24:49 PM ET
    $SLQT
    Specialty Insurers
    Finance

    Chief Accounting Officer Fisher Stephanie D. converted options into 59,651 shares and covered exercise/tax liability with 25,266 shares, increasing direct ownership by 49% to 104,582 units (SEC Form 4)

    4 - SelectQuote, Inc. (0001794783) (Issuer)

    8/5/25 9:24:35 PM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    SEC Filings

    View All

    SEC Form 10-K filed by SelectQuote Inc.

    10-K - SelectQuote, Inc. (0001794783) (Filer)

    8/21/25 5:11:03 PM ET
    $SLQT
    Specialty Insurers
    Finance

    Amendment: SelectQuote Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K/A - SelectQuote, Inc. (0001794783) (Filer)

    8/21/25 5:08:36 PM ET
    $SLQT
    Specialty Insurers
    Finance

    SelectQuote Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SelectQuote, Inc. (0001794783) (Filer)

    8/21/25 7:34:29 AM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Devine Denise L bought $14,460 worth of shares (4,000 units at $3.62), increasing direct ownership by 1% to 318,583 units (SEC Form 4)

    4 - SelectQuote, Inc. (0001794783) (Issuer)

    3/19/25 4:54:26 PM ET
    $SLQT
    Specialty Insurers
    Finance

    SEC Form 4: Matthews Joshua Brandon bought $113,295 worth of shares (97,500 units at $1.16), increasing direct ownership by 32% to 400,937 units

    4 - SelectQuote, Inc. (0001794783) (Issuer)

    9/18/23 6:29:01 PM ET
    $SLQT
    Specialty Insurers
    Finance

    SEC Form 4: Grant William Thomas Iii bought $179,250 worth of shares (150,000 units at $1.20), increasing direct ownership by 9% to 1,913,851 units

    4 - SelectQuote, Inc. (0001794783) (Issuer)

    9/18/23 6:28:20 PM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    Financials

    Live finance-specific insights

    View All

    SelectQuote, Inc. Reports Fourth Quarter of Fiscal Year 2025 Results

    Fourth Quarter of Fiscal Year 2025 – Consolidated Earnings Highlights Revenue of $345.1 million Net income of $12.9 million Adjusted EBITDA* of $2.7 million Fiscal Year 2026 Guidance Ranges: Revenue expected in a range of $1.650 billion to $1.750 billion Adjusted EBITDA* expected in a range of $120 million to $150 million Fourth Quarter Fiscal Year 2025 – Segment Highlights Senior Revenue of $82.5 million Adjusted EBITDA* of $7.7 million Approved Medicare Advantage policies of 85,344 Healthcare Services Revenue of $214.0 million Adjusted EBITDA* of $11.9 million 108,018 SelectRx members Life Revenue of $48.0 million Adjusted EBITDA* of $6

    8/21/25 7:30:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    SelectQuote to Release Fiscal Fourth Quarter and Full Year 2025 Earnings on August 21

    SelectQuote, Inc. (NYSE:SLQT), a leading distributor of Medicare insurance policies and owner of a rapidly growing Healthcare Services platform, today announced it will release its fourth quarter and full year 2025 financial results before market open on Thursday, August 21, 2025. Chief Executive Officer, Tim Danker, and Chief Financial Officer, Ryan Clement, will host a conference call on the day of the release (August 21, 2025) at 8:30 am ET to discuss the results. To register for this conference call, please use this link: https://registrations.events/direct/Q4I547808. After registering, a confirmation will be sent via email, including dial in details and unique conference call codes

    8/7/25 7:30:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    SelectQuote, Inc. Reports Third Quarter of Fiscal Year 2025 Results

    Third Quarter of Fiscal Year 2025 – Consolidated Earnings Highlights Revenue of $408.2 million Net income of $26.0 million Adjusted EBITDA* of $37.7 million Fiscal Year 2025 Guidance Ranges: Revenue expected in a range of $1.500 billion to $1.575 billion Net income (loss) expected in a range of $(1) million to $28 million Adjusted EBITDA* expected in a range of $115 million to $140 million Third Quarter Fiscal Year 2025 – Segment Highlights Senior Revenue of $169.4 million Adjusted EBITDA* of $45.7 million Approved Medicare Advantage policies of 168,001 Healthcare Services Revenue of $189.6 million Adjusted EBITDA* of $6.4 million 105,523 SelectRx members Li

    5/12/25 7:30:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by SelectQuote Inc. (Amendment)

    SC 13G/A - SelectQuote, Inc. (0001794783) (Subject)

    1/29/24 3:26:24 PM ET
    $SLQT
    Specialty Insurers
    Finance

    SEC Form SC 13G/A filed by SelectQuote Inc. (Amendment)

    SC 13G/A - SelectQuote, Inc. (0001794783) (Subject)

    2/14/23 1:42:28 PM ET
    $SLQT
    Specialty Insurers
    Finance

    SEC Form SC 13G/A filed by SelectQuote Inc. (Amendment)

    SC 13G/A - SelectQuote, Inc. (0001794783) (Subject)

    2/1/23 4:54:05 PM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    Leadership Updates

    Live Leadership Updates

    View All

    SelectQuote Names Ryan Clement as Chief Financial Officer

    Clement has served as Interim CFO since May 2022 SelectQuote, Inc. (NYSE:SLQT) today announced that the Board of Directors appointed Ryan Clement, SVP of Financial Planning & Analysis, to serve as the company's Chief Financial Officer. Clement was named interim CFO in May 2022. CEO Tim Danker commented, "Over the last year, Ryan has excelled as our Interim CFO and has demonstrated both the financial acumen and leadership qualities we are looking for in the company's next permanent CFO. Ryan has played a critical role in our strategic redesign that has vastly improved SelectQuote's operating results and financial stability and positions the company to execute on our objectives in the futur

    2/22/23 8:00:00 AM ET
    $SLQT
    Specialty Insurers
    Finance